Sanofi to Acquire Synthorx for $2.5B

 Sanofi to Acquire Synthorx for $2.5B

Sanofi to Acquire Synthorx for $2.5B

Shots:

  • Sanofi to acquire Synthrox in all-cash transactions at $68/share, making a total deal value $2.5B with a premium of 172% to Synthorx’s closing price on December 6, 2019. The transaction is expected to be completed in Q1’20
  • The focus of the acquisition is to foster Sanofi’s immuno-oncology (IO) pipeline with the addition of Synthorx’s THOR-707. Additionally, Synthorx’s Expanded Genetic Alphabet platform is expected to display synergistic effect with Sanofi’s platforms including Nanobody technology, enabling it to develop novel therapies for oncology and other therapeutic areas
  • Synthorx’s THOR-707 is a variant of IL-2, being evaluated for multiple solid tumors as monothx or in combination with immune checkpoint inhibitors. Sanofi expects THOR-707 to shown therapeutic activity when combined with its pre/-clinical oncology assets including PD-1, CD-38, and molecules modulating effector T-cells and NK cells and pursue it as a foundation of future IO-IO combinations

Click here to­ read full press release/ article | Ref: Businesswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post